The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Exciting advances in the field of CLL
Christine Ryan
• 10 Jun 2022
Christine Ryan, MD, Dana-Farber Cancer Institute, Boston, MA, shares her excitement for advances in targeted therapies for chronic lymphocytic leukemia (CLL), including next-generation BTK inhibitors. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
